Gilead Sciences, under pressure from a flagging hep C franchise, agreed to plunk down nearly $12 billion for Kite Pharma just ahead of a blockbuster CAR-T…

The Big Pharma workforce in 2007 appears remarkably similar to the present. Underneath those numbers, though, are some major shifts.

Fosun Pharma and Shanghai Pharma are bidding for a stake in U.S. drugmaker Arbor Pharma.

The generics pricing hit that's slammed Teva shares over last week? The company knew it was coming—and stayed mum for five weeks.

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Over the past 10 years, we’ve covered scores of deals—and rumors of deals—and now, we're asking you to choose the best and worst of them.

FiercePharma kept track as the industry launched drugs, made deals, lost patents, shrank, grew, innovated and revolutionized since 2007. Here's how.

Gilead Sciences is said to be evaluating United Therapeutics, although it finds itself in competition with GlaxoSmithKline and perhaps others.